---
title: "Akeso falls 6% as FDA declines ivonescimab U.S. application"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306201510.md"
description: "Akeso fell 6.07% to HK$57.30 after FDA declined ivonescimab's initial U.S. application over China-heavy data."
datetime: "2026-11-20T01:51:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306201510.md)
  - [en](https://longbridge.com/en/news/306201510.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306201510.md)
generator: "portal-rs"
---

# Akeso falls 6% as FDA declines ivonescimab U.S. application

Akeso (9926.HK) fell more than **6%** in Hong Kong trading to **HK$57.30**.

The biotechnology industry index fell 3.9% over the same period.

The U.S. Food and Drug Administration declined the initial marketing application for ivonescimab, citing that **93%** of trial data came from Chinese patients, which limits applicability to the U.S. population. The FDA had previously raised concerns about enrollment practices, noting delayed recruitment in North America and Europe. The stock tumbled **22.11%** the previous day, erasing about **HK$17 billion** in market value.

Chairman Xia Yu acknowledged shortcomings in the trial design and said the rejection applies only to a specific later-line indication. Global clinical development and key HARMONi-3 data readouts remain unaffected, and the company is considering share buybacks to stabilize the market.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**